Search clinical trials for: immunogenic cell death

Total 54167 results

Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
European Organisation for Research and Treatment...

Completed

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Ovarian Neoplasms

Spain, Switzerland, Netherlands, United Kingdom, France
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

HIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)

United States, Australia, Canada, Puerto Rico
Crozer-Keystone Health System
Saint Peters University Hospital; Community Medical Center, Toms River, NJ

Completed

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect (I-SABR)

Non Small Cell Lung Cancer | Metastatic Nonsmall Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Multiple Myeloma | Relapsed/Refractory

United States
Cellid Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

COVID-19 | Vaccines

Korea, Republic of
Chulalongkorn University
National Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... and other collaborators

Completed

ChulaCov19 Vaccine in Healthy Adults

COVID-19 Vaccine | Safety Issues

Thailand
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Renal Cell Carcinoma

China
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Human Papilloma Virus Infection

China
Yu Qin

Active, not recruiting

An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Prevention of COVID-19 Caused by SARS-CoV-2

China
Yisheng Biopharma (Singapore) Pte. Ltd.

Completed

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

COVID-19 Pandemic

United Arab Emirates
National Institute of Allergy and Infectious Diseases...

Completed

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

HIV Infections

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Belgium, Israel, Spain
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Lassa Fever

Ghana
Inovio Pharmaceuticals

Withdrawn

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Coronavirus Infection
Zhejiang Provincial Center for Disease Control...
Liaoning Chengda Biotechnology CO., LTD

Active, not recruiting

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

Japanese Encephalitis | Vaccine Reaction | Vaccine Preventable Disease

China
Merck Sharp & Dohme LLC

Completed

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)

Non-Small Cell Lung Cancer

United States, Canada, Hungary, Israel, Spain
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Non-small Cell Lung Carcinoma
Merck Sharp & Dohme LLC

Terminated

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis

United States, Canada, Israel
University of Cologne

Withdrawn

Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors (SPICE)

Melanoma | Non Small Cell Lung Cancer

Germany
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Non-Small-Cell Lung Cancer
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Melanoma | Carcinoma, Non-Small-Cell Lung

India
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Small Cell Lung Cancer (SCLC)

United States, Australia, Canada, Chile, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Switzerland, Taiwan, Turkey, United Kingdom
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

Hepatocellular Carcinoma
Jiangsu Rec-Biotechnology Co., Ltd.
Iqvia Pty Ltd

Completed

Safety, Reactogenicity and Immunogenicity Study of ReCOV

Covid19

New Zealand
Nina Bhardwaj
Memorial Sloan Kettering Cancer Center; NYU Langone Health; Ludwig Institute... and other collaborators

Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Yonsei University

Completed

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Recurrent/Metastatic Gastric Cancer

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Completed

Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease (DREVAC)

Sickle Cells Disease | Invasive Pneumococcal Infections

France
PT. Kimia Farma (Persero) Tbk

Active, not recruiting

The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine

COVID-19

Indonesia
Merck Sharp & Dohme LLC

Completed

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Neoplasms | Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Hodgkin Lymphoma
Jiangsu Province Centers for Disease Control and...

Active, not recruiting

Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Completed

Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly

COVID-19

China
Sinovac Research and Development Co., Ltd.

Suspended

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

COVID-19

China
Sinovac Research and Development Co., Ltd.

Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19

Turkey
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

COVID-19

China
Sinovac Biotech Co., Ltd

Completed

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

COVID-19

China
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Melanoma | Solid Tumors
International Vaccine Institute
Inovio Pharmaceuticals; Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Coronavirus Infection | SARS-CoV 2

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Advanced/Metastatic Solid Tumors

United States, Canada

3

Subscribe